|1.||Perova, N V: 4 articles (03/2007 - 01/2003)|
|2.||Li, Yi: 3 articles (12/2014 - 05/2010)|
|3.||Sokolov, E I: 3 articles (01/2006 - 01/2003)|
|4.||Couroucli, Xanthi I: 2 articles (05/2015 - 12/2008)|
|5.||Jiang, Weiwu: 2 articles (05/2015 - 12/2008)|
|6.||Moorthy, Bhagavatula: 2 articles (05/2015 - 12/2008)|
|7.||Zhen, Yong-Su: 2 articles (12/2014 - 05/2010)|
|8.||Zhen, Yongsu: 2 articles (09/2010 - 10/2009)|
|9.||Miao, Qingfang: 2 articles (09/2010 - 10/2009)|
|10.||Cai, Lin: 2 articles (05/2010 - 10/2009)|
05/01/1990 - "These studies suggest that in normolipidaemic Type 2 diabetic patients, the apoprotein composition of VLDL is abnormal and this may alter VLDL macrophage interactions and thus contribute to the increased prevalence of atherosclerosis in diabetic patients."
09/01/1975 - "These studies were performed in light of the possible importance of these apoproteins in both lipid metabolism and the pathogenesis of atherosclerosis. "
01/01/2014 - "The apoprotein misfolding in LDL(-) emerges as a possible significant trigger mechanism of atherogenesis. "
08/31/2010 - "The peculiar feature of LDL(-) is an apoprotein misfolding that triggers the formation of aggregates, perfectly fitting in size the subendothelial droplets observed in early phases of atherogenesis. "
11/01/2006 - "CysGly seems to compete with Hcy for binding to LDL apoprotein, suggesting that CysGly may protect against atherosclerosis by decreasing the concentrations of Hcy transferred by LDL from plasma to endothelial and subendothelial spaces."
09/01/2000 - "These data lend further credit to a physiological function of SP-A in regulating alveolar host defense and inflammation by suggesting a fundamental role of this apoprotein in limiting excessive proinflammatory cytokine release in pulmonary Mphi during ARDS."
04/01/1983 - "A non-CRP apoprotein present in low amounts in VLDL from normal rabbit plasma appears to increase in VLDL as inflammation progresses. "
02/01/2012 - "We compared plasma lipids, Apoprotein-AI and hs-CRP, as a marker of chronic inflammation. "
12/01/2003 - "PGA (prothrombin time, GGT, apoprotein A1) index, PGAA (PGA+delta2-macroglobulin) index, albumin and albumin/globulin were relevant to both inflammation and fibrosis. "
05/01/1999 - "The results show a relatively high level of triglyceridemia, a decreased level of total cholesterol, apoproteins A1 and B and a hypergammaglobulinemia with concomitant and significant increase in the level of orosomucoide as a stigmate of inflammation. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
08/01/1987 - "Rather, a slight improvement in glycemic control and alterations in the apoprotein compositions in favor of decreased risk for coronary artery disease may occur."
10/01/1992 - "The aims of this study were to evaluate plasma lipid, apoprotein and Lp(a) levels in patients with severe coronary atherosclerosis undergoing aorto-coronary bypass surgery (BP) and to relate these parameters to the involvement of one or more vessels. "
04/01/1991 - "The study of serum apoprotein levels as indicators for the severity of angiographically assessed coronary artery disease."
01/01/2007 - "In men with coronary atherosclerosis we revealed elevated level of small dense LDL and substantially oxidized lipid and apoprotein components of these particles. "
02/01/1993 - "We conclude that if abnormal apoprotein levels during childhood are found to be a valued predictor of premature coronary artery disease, then family history of premature coronary artery disease can be used to select children for determination and assessment of their coronary risk."
|4.||Coronary Disease (Coronary Heart Disease)
09/01/1980 - "As compared to suitable normal controls, patients with angiographically documented coronary heart disease showed significant changes in all lipid and apoprotein concentrations under study. "
05/01/1999 - "Polymorphism in apoprotein-CIII gene and coronary heart disease."
09/01/1988 - "Recent evidence indicates that measurement of apoproteins may enhance evaluation of coronary heart disease risk. "
09/27/1986 - "Apoproteins: predictors of coronary heart disease?"
07/19/1985 - "Seven lipid parameters, including apoproteins A1, A2 and B were determined in blood from different parts of the cardiovascular system in two groups of patients one with and the other without coronary heart disease. "
02/01/1993 - "The predictive value of family history is more reliable for detecting abnormal apoprotein ratio than for detection of hypercholesterolemia. "
09/01/1980 - "These data suggest that lipid and apoprotein levels at 7 days are more representative than cord-blood levels and more meaningful for a screening of congenital hypercholesterolemia. "
05/01/1999 - "The variant allele of apoprotein-CIII was found to be associated neither with hypertriglyceridemia nor with hypercholesterolemia. "
01/01/1989 - "These results suggest that factors other than chemical composition (perhaps surface charge or apoprotein conformation changes) influence PG-LDL binding and that the assessment of PG-LDL binding is useful in predicting atherosclerosis in animals that do not respond to hypercholesterolemia by increasing LDL size."
12/01/1995 - "Based on these considerations, we studied 15 patients affected by primary hypercholesterolemia to evaluate the effect of simvastatin in Lp(a) and apoprotein plasma levels (A1, B, C2, C3, E), in addition to the classic lipid parameters. "
|2.||Apolipoprotein A-I (Apolipoprotein A1)
|4.||Apolipoproteins B (ApoB)
|7.||Apolipoproteins E (ApoE)
|1.||Renal Dialysis (Hemodialysis)
|3.||Transplantation (Transplant Recipients)